Press release, Helsinki, 26 April 2024 at 3 PM (EEST)

Neurosurgery Customer from Germany Orders Nexstim NBS System 5

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an existing customer hospital in Germany. The system will be used in neurosurgery.

The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech function. The information gained from the mapping may be used in pre-procedural planning.

Mikko Karvinen, CEO of Nexstim, comments: “Our diagnostics system offers a unique possibility for neurosurgeons to receive crucial information about the location of vital functional areas before a surgery. We are happy to have one of our existing customers in Germany order a new NBS 5 system. This is a clear sign of the commitment that the Nexstim team has in maintaining long-term customer relationships in this important market, and of the real difference that our products are making in the everyday work of neurosurgeons and other medical professionals.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com

Attachment

• Nexstim Plc_Press release_EU order_26042024_FINAL